Although the anti-tissue transglutaminase antibody (anti-tTG) has proven to be an excellent biomarker for identifying celiac disease [1], D-IBS remains a diagnosis of exclusion since the clinical criteria for IBS (Rome Criteria [2–6]) do not exclude IBD. This evidence concerns the gene TGM2 and irritable bowel syndrome.